 ST. GALLEN, Switzerland STAMFORD, Conn.--BUSINESS WIRE--Regulatory News: Vifor Pharma and Cara Therapeutics Nasdaq:CARA today announced that the U.S. Food and Drug Administration FDA has approved KORSUVATM difelikefalin for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. KORSUVATM injection is a first-in-class kappa opioid receptor KOR agonist that targets the bodys peripheral nervous system. The KOR 